Tvardi Therapeutics, Inc. (TVRD) — 8-K Filings

8-K Filings (26)

• 8-K Filing — May 8, 2026
• Tvardi Therapeutics Appoints New Directors and CMO — Dec 18, 2025 Risk: medium
  Tvardi Therapeutics, Inc. announced on December 16, 2025, changes in its board of directors and executive compensation. Specifically, the company elected two ne
• Tvardi Therapeutics Files 8-K — Nov 19, 2025 Risk: low
  Tvardi Therapeutics, Inc. filed an 8-K on November 19, 2025, reporting on Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly
• Tvardi Therapeutics Files 8-K — Oct 14, 2025 Risk: medium
  Tvardi Therapeutics, Inc. filed an 8-K on October 14, 2025, reporting on events that occurred on October 13, 2025. The filing indicates a change in the company'
• Tvardi Therapeutics Files 8-K on Financials — Aug 14, 2025 Risk: low
  Tvardi Therapeutics, Inc. filed an 8-K on August 14, 2025, reporting on its results of operations and financial condition. The filing also includes financial st
• Tvardi Therapeutics Appoints New CEO, Dr. Jonathan Lim — Jul 14, 2025 Risk: medium
  Tvardi Therapeutics, Inc. announced on July 8, 2025, the appointment of Dr. Jonathan Lim as Chief Executive Officer and a member of the Board of Directors. Dr.
• 8-K Filing — Jun 9, 2025
• Tvardi Therapeutics Files 8-K — May 27, 2025 Risk: low
  Tvardi Therapeutics, Inc. filed an 8-K on May 27, 2025, reporting on financial statements and exhibits. The company, formerly known as Cara Therapeutics, Inc.,
• Tvardi Therapeutics Reports Material Definitive Agreement & Acquisition — Apr 15, 2025 Risk: medium
  Tvardi Therapeutics, Inc. filed an 8-K on April 15, 2025, reporting several material events. These include the entry into a material definitive agreement, compl
• 8-K Filing — Apr 11, 2025
• Cara Therapeutics Files 8-K — Apr 1, 2025 Risk: low
  Cara Therapeutics, Inc. filed an 8-K on April 1, 2025, reporting on matters submitted to a vote of security holders, other events, and financial statements/exhi
• Cara Therapeutics to be Acquired by PolyPid Ltd. — Mar 24, 2025 Risk: medium
  Cara Therapeutics, Inc. announced on March 24, 2025, that it has entered into a definitive agreement to be acquired by PolyPid Ltd. for approximately $375 milli
• PolyPid to Acquire Cara Therapeutics for $93.3M — Jan 21, 2025 Risk: medium
  Cara Therapeutics, Inc. announced on January 16, 2025, that it has entered into a definitive agreement to be acquired by PolyPid Ltd. for approximately $93.3 mi
• Viatris to Acquire Cara Therapeutics for $3.00/share + CVR — Jan 17, 2025 Risk: medium
  Cara Therapeutics, Inc. announced on January 14, 2025, that it has entered into a definitive agreement to be acquired by Viatris Inc. for $3.00 per share in cas
• Cara Therapeutics Files 8-K — Dec 30, 2024 Risk: low
  Cara Therapeutics, Inc. filed an 8-K on December 30, 2024, reporting amendments to its articles of incorporation or bylaws and financial statements and exhibits
• PolyPid to Acquire Cara Therapeutics for $375M — Dec 18, 2024 Risk: medium
  Cara Therapeutics, Inc. announced on December 17, 2024, that it has entered into a definitive agreement to be acquired by PolyPid Ltd. for approximately $375 mi
• Cara Therapeutics Faces Delisting Concerns — Nov 22, 2024 Risk: high
  Cara Therapeutics, Inc. filed an 8-K on November 22, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, and a tra
• Cara Therapeutics Faces Delisting Concerns — Aug 1, 2024 Risk: high
  Cara Therapeutics, Inc. filed an 8-K on August 1, 2024, reporting a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard. The filing i
• Cara Therapeutics Reports Exit/Disposal Costs — Jun 18, 2024 Risk: medium
  Cara Therapeutics, Inc. filed an 8-K on June 18, 2024, reporting costs associated with exit or disposal activities as of June 14, 2024. The filing indicates the
• Cara Therapeutics Files 8-K — Jun 12, 2024 Risk: low
  On June 12, 2024, Cara Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Other Events, with no specific financi
• Cara Therapeutics Files 8-K on Shareholder Votes and Financials — Jun 7, 2024 Risk: low
  Cara Therapeutics, Inc. filed an 8-K on June 7, 2024, reporting on matters submitted to a vote of security holders and financial statements as of June 4, 2024.
• Cara Therapeutics Files 8-K for Financials — May 13, 2024 Risk: low
  Cara Therapeutics, Inc. filed an 8-K on May 13, 2024, reporting results of operations and financial condition, along with financial statements and exhibits. The
• Cara Therapeutics Announces Executive Changes — Mar 22, 2024 Risk: medium
  Cara Therapeutics, Inc. announced on March 19, 2024, the departure of its Chief Medical Officer, Dr. Joana Neves. The company also announced the appointment of
• Cara Therapeutics Files 8-K on Financials — Mar 4, 2024 Risk: low
  Cara Therapeutics, Inc. filed an 8-K on March 4, 2024, reporting on its results of operations and financial condition. The filing also includes financial statem
• Cara Therapeutics Changes Business Address to 400 Atlantic St, Stamford — Feb 2, 2024
  Cara Therapeutics, Inc. filed an 8-K on February 2, 2024, to report a change in its business address. The company's principal executive offices moved from 4 Sta
• Cara Therapeutics 8-K: Exit/Disposal Activities, Reg FD Disclosure — Jan 22, 2024
  Cara Therapeutics, Inc. filed an 8-K on January 22, 2024, reporting an event that occurred on January 17, 2024, related to 'Cost Associated with Exit or Disposa

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX